7 Best Peptides for Endurance

What to Know Before Choosing a Peptide for Endurance

The word "endurance" covers a lot of ground physiologically, and the peptides people reach for reflect that. Some are aimed at mitochondrial efficiency and fuel metabolism, trying to extend the point at which fatigue sets in. Others are used for recovery, keeping tendons, muscles, and connective tissue healthy enough to absorb a high training load week after week. A few sit in both categories. There is no single compound that has been approved, tested in large human trials, and confirmed to improve endurance across the board. What exists is a field of compounds people are genuinely using, each targeting a different lever, with evidence that ranges from robust to essentially theoretical.

A compound earns a slot on this list because people use it for endurance, or are actively discussing using it for that purpose. FDA-approved, telemedicine-prescribed, and research-only compounds are all eligible. Evidence strength is never the filter for inclusion; it is what we describe honestly inside each entry. So you will find compounds here with multiple human randomized controlled trials behind them, and you will find compounds with nothing but animal models and community reports. Both kinds belong on an honest map of what people are actually doing.

Two entries, SLU-PP-332 and 5-Amino-1MQ, are small molecules rather than peptides in the strict chemical sense. They appear here because they come up constantly in endurance-peptide conversations and their mechanisms overlap closely with the rest of the list. The article uses "peptides" the way the community does: as a shorthand for the broader class of compounds people discuss in this context.

The numbers in front of each entry are a spine for the list, not a verdict. They reflect how prominently each compound appears in the research and in documented real-world use for endurance, not a recommendation that one compound is better than another for you. Your health history, your specific goals, and what else you are using all shape which of these, if any, belongs in a personalized plan. That is the work the MyPeptidePal app is built to do.

1. MOTS-c: The Mitochondrial Exercise Mimetic

MOTS-c stands for Mitochondrial Open Reading Frame of the 12S rRNA-c, which sounds intimidating until you understand what it does. It is a small signaling molecule produced inside the mitochondria, the organelles that generate the cellular energy currency ATP, and its job is to communicate metabolic stress to the rest of the cell. Think of it as an internal alarm system: when the body is under energy demand from exercise or caloric restriction, MOTS-c moves from the mitochondria into the cell nucleus and switches on a set of genes that improve how the cell handles fuel.

The primary pathway is AMPK activation. AMPK is sometimes called the master metabolic switch of the cell, the same mechanism triggered by vigorous exercise, caloric restriction, and the diabetes drug metformin. When AMPK turns on, glucose uptake in skeletal muscle increases, fatty acid oxidation improves, and mitochondrial biogenesis, the process of building new mitochondria, gets a push. For endurance athletes, what that translates to in theory is better fuel efficiency: more energy extracted from fat during prolonged effort and less dependence on glycogen stores that deplete during hard extended exercise.

The catch is that the human evidence base is essentially absent. Animal studies are compelling. Research in rodents has shown substantial increases in treadmill capacity and measurable restoration of ATP production in older animals. Natural MOTS-c levels in the blood have also been observed to rise after sustained endurance training in humans, suggesting the molecule plays a genuine role in exercise adaptation. But no published randomized controlled trial has measured MOTS-c's effect on VO2 max, time-trial performance, or any other endurance outcome in human subjects as of 2026. Human trials are described in the literature as ongoing, but results have not been published.

In community discussions, MOTS-c is the most frequently cited compound for direct endurance enhancement. Athletes report using it before workouts to boost stamina and improve how the body manages fuel when glycogen runs low. It is administered subcutaneously, is not approved by the FDA for any human use, and is prohibited under WADA's S0 category, which covers any non-approved pharmacological substance. Competitive athletes subject to testing should treat it as prohibited regardless of any specific listing status.

2. BPC-157: For Staying Healthy Enough to Train

BPC-157, short for Body Protection Compound-157, is a synthetic peptide derived from a protein found in gastric juice. It does not directly improve aerobic capacity or mitochondrial function. Its place on this list comes from how high-volume endurance athletes actually use it: to manage the cumulative tissue stress that derails training blocks before they deliver their full benefit.

The mechanisms most relevant for endurance use are vascular and structural. BPC-157 promotes VEGF upregulation, which triggers angiogenesis, the growth of new blood vessels into damaged or stressed tissue. More blood vessels to a tendon or muscle means faster delivery of oxygen and nutrients, which is the theoretical basis for accelerated healing. It also appears to influence nitric oxide synthesis, promoting vasodilation and improved blood flow to working tissue. In animal models these effects are well-documented: tendon repair, muscle healing, and gut protection all show up reliably in the preclinical literature.

The human evidence is limited to the point where mainstream sports medicine has become critical of the claims commonly made online. A 2026 editorial from the American Orthopaedic Society for Sports Medicine noted explicitly that no randomized controlled trials in human subjects exist for BPC-157. What has been published is a small retrospective case series of 12 patients reporting subjective improvement and a two-person pilot study. Those data points exist, but they do not support strong performance claims. The honest framing is this: the animal data is real and interesting, and the human confirmation is essentially absent.

In endurance communities covering Hyrox, triathlon, and ultramarathon preparation, BPC-157 is used more for injury prevention and recovery than for direct performance enhancement. The practical logic is straightforward: if an overuse injury takes three weeks of training away, anything that shortens that window meaningfully improves the training year. Community accounts include one ultramarathoner who reported a large increase in output after two weeks, alongside other users on the same forums who reported no discernible benefit for the same applications. The variability is real and worth naming. BPC-157 is not approved by the FDA for human use, and it is prohibited by WADA under S0.

3. TB-500: For Angiogenesis and Recovery Volume

TB-500 is a synthetic analog of Thymosin Beta-4, a naturally occurring protein involved in cell migration, tissue repair, and actin regulation. Actin is the structural protein that forms a large part of the cell's internal framework, and TB-500's primary mechanism involves binding to actin in a way that promotes the movement of cells toward areas of damage. That cellular migration is the foundation of how the compound supports tissue repair.

For endurance athletes, the most relevant mechanism is angiogenesis. Like BPC-157, TB-500 promotes VEGF upregulation, which drives the formation of new blood vessels. Greater capillary density in muscle tissue means better oxygen delivery during exercise and faster clearance of metabolic byproducts during recovery. TB-500 is also described as having anti-fibrotic properties, meaning it may reduce the formation of scar tissue in repeatedly stressed connective tissue, which matters for athletes logging large weekly mileage over many months.

No human clinical trial data exists for TB-500 in endurance or athletic performance contexts as of 2026. The preclinical literature on wound healing and tissue repair is substantive, but the translation to athletic use in humans has not been formally studied. Its reputation in the fitness community is built entirely on user-reported experience, and it is consistently among the most discussed recovery compounds in triathlon, cycling, and ultramarathon circles.

In practice, TB-500 is frequently paired with BPC-157 in what the community refers to as a recovery protocol, with the combination described as a standard for managing tissue resilience under sustained training load. Athletes report using the pairing to sustain training frequency by reducing soreness and supporting faster turnaround between hard sessions. TB-500 is a research chemical, not approved by the FDA, and prohibited by WADA under S0.

4. Collagen Peptides: The Evidence-Backed Foundation

Collagen peptides occupy a genuinely different category from every other entry on this list. They are hydrolyzed food-derived proteins, not synthetic research chemicals. They require no prescription, no gray-market sourcing, and no injection. And they have the strongest human evidence base of anything discussed here for endurance-related outcomes.

A 2024 meta-analysis covering 19 randomized controlled trials found significant improvements in fat-free mass, strength, and tendon adaptations with collagen peptide supplementation. Human trial data has shown improved performance in running time trials, better tendon mechanics under load, and structural improvements in connective tissue. For endurance athletes, the most practically relevant benefit is joint and tendon health: tendons and ligaments are the limiting factor in training volume for a large proportion of athletes, and collagen peptides are among the few interventions with solid human evidence for supporting those structures under repetitive stress.

The mechanism is less glamorous than AMPK activation or mitochondrial biogenesis but well understood. Hydrolyzed collagen provides amino acid precursors, particularly glycine and proline, that the body uses to synthesize new collagen in tendons and ligaments. The research suggests timing around exercise may influence how well those precursors reach the relevant tissue, though the details of optimal timing are still being refined.

Collagen peptides are fully legal for competitive athletes, carrying no WADA prohibition. They are recognized as safe by the FDA as a food supplement. For athletes who need a pragmatic starting point, or who compete in tested sport and cannot use anything on the WADA prohibited list, collagen peptides are the evidence-anchored foundation of an endurance support approach.

5. SLU-PP-332: The ERR Agonist Exercise Mimetic

SLU-PP-332 is not a peptide. It is a synthetic small molecule that functions as a pan-ERR agonist, meaning it activates a family of transcription factors called estrogen-related receptors, specifically ERR alpha, beta, and gamma. Those receptors, despite their name, have nothing to do with estrogen in this context; they are switches that control the expression of genes involved in oxidative metabolism and mitochondrial function. Activating them with SLU-PP-332 is meant to replicate, at the cellular level, what chronic endurance training does to muscle over time: increase mitochondrial density, shift muscle fibers toward oxidative types that are more fatigue-resistant, and improve fat burning efficiency.

The compound appears in endurance discussions because its mechanism targets the same adaptations that years of aerobic training produce, which is why it carries the exercise mimetic classification. In animal models, SLU-PP-332 increased endurance capacity and produced measurable changes in muscle fiber composition consistent with trained muscle. That preclinical data is what drives community interest.

The evidence in humans is absent. No published human clinical trial has tested SLU-PP-332 for endurance or any other outcome as of 2026, and no human safety data exists. The compound is a research chemical with no regulatory approval in any country and no established safety profile in people. Community discussion of SLU-PP-332 is based entirely on mechanistic extrapolation from the animal data.

It is worth noting that SLU-PP-332 sometimes appears alongside Cardarine (GW501516), another non-peptide exercise mimetic that carries significant carcinogenicity findings from animal studies. SLU-PP-332's mechanism is distinct, and those concerns do not automatically transfer. But with no human safety data, that gap simply has not been evaluated yet. The risk profile for SLU-PP-332 in people is genuinely unknown.

6. AOD-9604: For Fuel Partitioning and Fat Metabolism

AOD-9604, which stands for Anti-Obesity Drug 9604, is a synthetic peptide fragment corresponding to a region of the human growth hormone molecule specifically associated with fat breakdown rather than growth-promoting effects. The intent in its original development was to capture the fat-metabolizing properties of growth hormone without stimulating IGF-1 production, which carries concerns around cancer risk and other systemic effects at pharmacological levels.

Its proposed relevance for endurance is indirect. Better fat oxidation means the body becomes more efficient at running on fat as a fuel, which theoretically spares glycogen stores and extends the window before fatigue-inducing depletion occurs. In long-duration aerobic events where the ability to use fat as fuel efficiently is a meaningful performance variable, improved fuel partitioning is a legitimate mechanistic target. The absence of significant IGF-1 stimulation also distinguishes AOD-9604 from full growth hormone and growth-hormone-releasing peptides in terms of certain risk considerations.

The human evidence for AOD-9604 is limited and focused on a different outcome entirely. It was studied during development as an obesity drug, and the trials that exist evaluated body composition and fat loss rather than aerobic capacity or endurance performance. No high-quality randomized controlled trial has demonstrated endurance improvement in humans. The drug development program was never completed through FDA approval, so while AOD-9604 has more human safety data behind it than a purely preclinical compound, that data does not address the endurance use case the community applies it to.

In community protocols, AOD-9604 is sometimes included in stacks oriented toward body recomposition alongside endurance work, on the reasoning that improved fat oxidation and body composition over time support aerobic performance. It is a research chemical, not approved by the FDA for any indication, and prohibited by WADA.

7. 5-Amino-1MQ: The NAD+ Upstream Lever

5-Amino-1MQ, full name 5-Amino-1-methylquinolinium, is another small molecule rather than a peptide in the strict sense, but like SLU-PP-332 it appears regularly enough in endurance-peptide conversations to belong on this list. Its mechanism is distinct from every other entry here: it inhibits NNMT, an enzyme called Nicotinamide N-methyltransferase, which regulates the availability of NAD+ inside cells.

NAD+ is a coenzyme that sits at the center of cellular energy metabolism. Higher intracellular NAD+ levels support mitochondrial function, activate a class of proteins called sirtuins (particularly SIRT1 and SIRT3) that regulate metabolic health and stress resistance, and feed into the same AMPK pathway that MOTS-c targets. The connection to endurance is made through this chain: more NAD+ means better-functioning mitochondria, which means more efficient ATP production under aerobic stress.

The endurance connection for 5-Amino-1MQ is theoretical rather than measured. The compound has been studied in preclinical models for metabolic health and obesity, and the NAD+-endurance relationship has some human support from trials on NMN, a direct NAD+ precursor that showed improved oxygen uptake and aerobic capacity in recreational runners over six weeks. But 5-Amino-1MQ's specific effects on endurance performance in humans have not been studied. No clinical trial data exists for this use as of 2026, and the compound carries no regulatory approval in any country. What circulates in community discussions is mechanistic reasoning based on its upstream position in the NAD+ pathway, applied to the established endurance biology of that pathway.

It shows up less frequently in community discussion compared to MOTS-c, BPC-157, or TB-500, and the people referencing it are generally those already exploring NAD+ precursors for metabolic optimization rather than those searching for a straightforward training edge.

How These Peptides Compare

Frequently Asked Questions

Are these endurance compounds legal for competitive athletes?

It depends entirely on which compound and which governing body. Collagen peptides are fully legal under WADA rules and available over the counter with no prescription. Every synthetic research compound on this list, including MOTS-c, BPC-157, TB-500, AOD-9604, SLU-PP-332, and 5-Amino-1MQ, falls under WADA's S0 category, which prohibits any non-approved pharmacological substance regardless of whether it is specifically named on the prohibited list. Competitive athletes subject to testing should treat all of the research-chemical entries as prohibited.

How do these compounds differ in what they actually target?

The list splits into two broad functional categories. MOTS-c, SLU-PP-332, and 5-Amino-1MQ are aimed at mitochondrial function and metabolic efficiency, targeting the cellular machinery that determines how efficiently the body converts fuel into movement. BPC-157, TB-500, and collagen peptides are aimed at tissue recovery and structural health, supporting the tendons, muscles, and connective tissue that absorb the load of high training volume. AOD-9604 sits between them, with its primary effect on fat metabolism carrying indirect implications for both fuel use and body composition over time.

Why is the human evidence so limited for most of these?

Most of the synthetic research compounds on this list were never developed for athletic performance use, and the regulatory and financial pathway for approving a compound solely for that purpose is both expensive and uncertain. Preclinical animal data is cheaper and faster to generate, and because many of these compounds circulate through gray-market channels, there is no commercial sponsor funding the human trials that would produce confirmatory evidence. The result is a field where the animal data is often genuinely interesting and the human confirmation is simply absent. That gap is what this article tries to describe honestly rather than paper over.

Does any compound on this list have a clean safety record?

Collagen peptides have a well-established safety profile from decades of food and supplement use, with minimal side effects observed in the research literature. The synthetic research compounds all carry meaningful unknowns. Gray-market sourcing introduces contamination risk on top of any compound-specific concerns. BPC-157 and growth-hormone-related compounds raise theoretical concerns around VEGF upregulation and cancer promotion. None of the research-chemical entries has the kind of large-scale, long-term human safety data that would support a clean safety characterization.

How long do people typically use these before noticing a difference?

Community protocols for the research compounds commonly run six to eight weeks, and reported effects, when they occur, are typically described as emerging across that window rather than appearing immediately. Collagen peptides have human trial data showing measurable tendon and performance outcomes over similar timeframes. The honest answer is that response varies considerably between individuals, and the absence of controlled human data for most of these compounds means there is no clinically established timeline to point to.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world use of peptides for endurance in one place.